Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005–2016
Authors:
Open Access
- 13 September 2022
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (11) , 2485-2495
Abstract
Multiple myeloma (MM) patients are predominantly elderly with comorbidities that have an impact on patient mortality and treatment decisions. We previously reported the patient characteristics and overall survival outcomes of the Finnish MM cohort diagnosed between 2005 and 2016 in a nationwide retrospective registry study comprising 3,851 adults. Here, we report detailed comorbidity characteristics for this real-world Finnish MM population at cohort entry and during follow-up. Data on diagnoses and causes of death were obtained from Finnish healthcare data registries and interrogated using various multistate time-to-event models. In the year preceding MM diagnosis, comorbidities (as per Charlson Comorbidity Index definition) were recorded in 38.0% of the cohort, of which 27.9% presented with pre-existing cardiovascular disease (CVD) and 4.8% had suffered a major adverse cardiac event (MACE). At 2 years post-MM diagnosis, cumulative incidence for CVD and MACE more than doubled to 57.1% and 11.4%, respectively, and only 31.9% of the cohort remained CVD-free. Prevalent secondary malignancies were recorded in 16.8% of the patient population at MM diagnosis, with cumulative incidence increasing steadily to 27.5% at 2 years and 33% at 5 years post-diagnosis. The main cause of mortality attributed to MM, CVD, secondary malignancy, or other causes remained stable throughout the follow-up, at an average of 74.2%, 9.4%, 9.8%, and 6.5%, respectively. Prevalence of CVDs and secondary malignancies is high in Finnish patients at MM diagnosis, with older male patients suffering from higher MACE and mortality risk. Proper recording and management of comorbidities alongside novel treatments remain crucial for optimal MM management.Keywords
Funding Information
- Takeda Pharmaceuticals International
This publication has 35 references indexed in Scilit:
- Cardiovascular Complications of Novel Multiple Myeloma TreatmentsCirculation, 2016
- Multiple Myeloma: Diagnosis and TreatmentMayo Clinic Proceedings, 2016
- Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score WorkMedical Care, 2015
- Cutaneous Malignant Neoplasms in Hematopoietic Cell Transplant RecipientsJAMA Dermatology, 2015
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataThe Lancet Oncology, 2014
- Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of PatientsBMC Medical Research Methodology, 2011
- The Problem With Composite End Points in Cardiovascular StudiesJACC, 2008
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987